TOP TEN perturbations for 39862_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39862_at
Selected probe(set): 214226_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39862_at (214226_at) across 6674 perturbations tested by GENEVESTIGATOR:
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):2.9467192Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
diphenylcyclopropenone study 1 (late) / diphenylcyclopropenone study 1 (early)
Relative Expression (log2-ratio):-2.4082031Number of Samples:6 / 10
| Experimental | diphenylcyclopropenone study 1 (late) |
| Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 4 to 8 months. ATC code:--- | |
| Control | diphenylcyclopropenone study 1 (early) |
| Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:--- |
diphenylcyclopropenone study 1 (early) / placebo treated skin tissue
Relative Expression (log2-ratio):2.3852854Number of Samples:10 / 11
| Experimental | diphenylcyclopropenone study 1 (early) |
| Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:--- | |
| Control | placebo treated skin tissue |
| Skin biopsy samples of healthy volunteers exposed to placebo for 3 days. |
atopic dermatitis study 21 (lesional; whole skin) / atopic dermatitis study 21 (non-lesional; whole skin)
Relative Expression (log2-ratio):2.1882591Number of Samples:5 / 5
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | atopic dermatitis study 21 (non-lesional; whole skin) |
| Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. |
atopic dermatitis study 21 (lesional; epidermis) / normal epidermis tissue
Relative Expression (log2-ratio):2.071331Number of Samples:5 / 10
| Experimental | atopic dermatitis study 21 (lesional; epidermis) |
| Lesional epidermal samples isolated from patient with moderate-to-severe chronic atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal epidermis tissue |
| Epidermal samples isolated from healthy subjects by laser capture microdissection. |
atopic dermatitis study 21 (lesional; epidermis) / atopic dermatitis study 21 (non-lesional; epidermis)
Relative Expression (log2-ratio):2.066742Number of Samples:5 / 5
| Experimental | atopic dermatitis study 21 (lesional; epidermis) |
| Lesional epidermal samples isolated from patient with moderate-to-severe chronic atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | atopic dermatitis study 21 (non-lesional; epidermis) |
| Non-lesional epidermal samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. |
atopic dermatitis study 12 (lesional; adults) / normal skin tissue (adults)
Relative Expression (log2-ratio):2.0500393Number of Samples:20 / 11
| Experimental | atopic dermatitis study 12 (lesional; adults) |
| Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | normal skin tissue (adults) |
| Skin biopsy samples from healthy adults (age range 38–57 years). |
atopic dermatitis study 12 (lesional; children) / normal skin tissue (children)
Relative Expression (log2-ratio):1.9150991Number of Samples:18 / 15
| Experimental | atopic dermatitis study 12 (lesional; children) |
| Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. | |
| Control | normal skin tissue (children) |
| Skin biopsy samples from healthy children (age range 4 months – 3 years) without personal/familial atopy. |
engineered skin substitute study 1 (late) / engineered skin substitute study 1 (early)
Relative Expression (log2-ratio):1.782196Number of Samples:3 / 2
| Experimental | engineered skin substitute study 1 (late) |
| Human skin substitutes tissue samples collected after 14 days in culture. | |
| Control | engineered skin substitute study 1 (early) |
| Human skin substitutes tissue samples collected after 3 days in culture. |
psoriasis study 11 (lesional; brodalumab; 15d; 350mg) / psoriasis study 11 (lesional; placebo; 15d)
Relative Expression (log2-ratio):-1.7594156Number of Samples:8 / 5
| Experimental | psoriasis study 11 (lesional; brodalumab; 15d; 350mg) |
| Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (350 mg s.c.) of brodalumab. ATC code: | |
| Control | psoriasis study 11 (lesional; placebo; 15d) |
| Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with placebo. |
Organism: Homo sapiens
Gene: 39862_at
Selected probe(set): 217949_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39862_at (217949_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Relative Expression (log2-ratio):-2.663826Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-28t28Z; post-infusion) |
| CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):2.4657478Number of Samples:2 / 2
| Experimental | conditioned medium study 1 (HS27a) |
| CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h. | |
| Control | untreated monocyte (CD14+) sample |
| Untreated CD14+ monocytes from two different donors. |
pancreatic cancer study 3 (ipmn) / normal pancreas tissue
Relative Expression (log2-ratio):-2.3970737Number of Samples:3 / 6
| Experimental | pancreatic cancer study 3 (ipmn) |
| Intraductal papillary mucinous neoplasm from patients with pancreatic cancer. | |
| Control | normal pancreas tissue |
| Normal human pancreatic tissue. |
conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):2.389431Number of Samples:2 / 2
| Experimental | conditioned medium study 1 (HS5) |
| CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h. | |
| Control | untreated monocyte (CD14+) sample |
| Untreated CD14+ monocytes from two different donors. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.3770418Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
retina pigment epithelium study 2 (fetal) / retina pigment epithelium study 1 (fetal)
Relative Expression (log2-ratio):2.3194876Number of Samples:12 / 6
| Experimental | retina pigment epithelium study 2 (fetal) |
| Human cultured fetal retina pigment epithelium samples obtained at gestation age between week 16-18. | |
| Control | retina pigment epithelium study 1 (fetal) |
| Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18. |
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.2920446Number of Samples:2 / 3
| Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.153741Number of Samples:2 / 3
| Experimental | glioma study 17 (small cell glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
Treg activation study 1 (300min) / unstimulated regulatory T-cell sample
Relative Expression (log2-ratio):-2.106142Number of Samples:2 / 2
| Experimental | Treg activation study 1 (300min) |
| Regulatory T-cells were stimulated for 300min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors. | |
| Control | unstimulated regulatory T-cell sample |
| Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors. |
Treg activation study 1 (280min) / unstimulated regulatory T-cell sample
Relative Expression (log2-ratio):-1.9960117Number of Samples:2 / 2
| Experimental | Treg activation study 1 (280min) |
| Regulatory T-cells were stimulated for 280min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors. | |
| Control | unstimulated regulatory T-cell sample |
| Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors. |